贝伐珠单抗联合XELOX方案对晚期结直肠癌患者肿瘤标志物水平及免疫功能的影响  

Effect of bevacizumab combined with XELOX regimen on tumor marker levels and immune function in patients with advanced colorectal cancer

作　　者：黄盼盼 Huang Pan-pan(Department of Oncology,Zhumadian Central Hospital,Zhumadian 463000,Henan,China)

机构地区：[1]驻马店市中心医院中西医结合肿瘤科,河南驻马店463000

出　　处：《四川生理科学杂志》2025年第4期763-765,880,共4页

摘　　要：目的:探讨贝伐珠单抗联合卡培他滨+奥沙利铂(Capecitabine+Oxaliplatin,XELOX)方案对晚期结直肠癌(Colorectal Cancer,CRC)患者肿瘤标志物水平及免疫功能的影响。方法:选取2022年1月至2023年12月期间我院收治的90例晚期CRC患者作为研究对象,以随机数字表法分为观察组和对照组,各45例。对照组采用XELOX方案治疗,观察组在对照组的基础上加用贝伐珠单抗。比较两组治疗效果、肿瘤标志物[糖类抗原199(Carbohydrate Antigen199,CA199)、(Carbohydrate Antigen 72-4,CA724)、癌胚抗原(Carcinoembryonic Antigen,CEA)]、免疫功能和毒副反应。结果:治疗后,两组肿瘤标志物和分化簇(Cluster of Differentiation,CD)8^(+)T细胞水平均显著降低,且观察组显著低于对照组(P<0.001);两组CD3^(+)、CD4^(+)T细胞水平、CD4^(+)/CD8^(+)比值均显著升高,且观察组显著高于对照组(P<0.001)。两组毒副反应发生率无明显差异(P>0.05)。结论:晚期CRC患者在常规化疗基础上加用贝伐珠单抗治疗能够提升临床治疗效果,利于降低肿瘤标志物水平,改善患者免疫功能,且毒副反应较少,值得临床广泛应用。Objective:Exploring the effects of bevacizumab combined with Capecitabine+Oxaliplatin(XELOX)regimen on tumor marker levels and immune function in patients with advanced colorectal cancer(CRC).Methods:A total of 90 late stage of CRC patients treated in our hospital from January 2022 to December 2023 were selected and grouped using a random number table method.45 cases in the control group were treated with XELOX regimen,and based on this,45 cases in the observation group were additionally treated with bevacizumab.Compare the therapeutic effects,tumor markers[carbohydrate antigen 199(CA199),carbohydrate Antigen 72-4(CA724),carcinoembryonic antigen(CEA)],immune function,and toxic side effects between two groups.Results:After treatment,both groups of tumor markers and Cluster of Differentiation(CD)8^(+)T cell levels were significantly reduced,and the observation group was significantly lower than the control group(P<0.001);Both groups showed significant increases in CD3^(+),CD4^(+),and CD4^(+)/CD8^(+),with the observation group being significantly higher than the control group(P<0.001).There was no significant difference in the incidence of toxic side effects between the both groups(P>0.05)Conclusion:The addition of bevacizumab to conventional chemotherapy in advanced CRC patients can improve clinical treatment efficacy,reduce tumor marker levels,improve patient immune function,and have fewer toxic side effects,which is worthy of widespread clinical application.

关 键 词：晚期结直肠癌 贝伐珠单抗 XELOX方案 肿瘤标志物 免疫功能 

分 类 号：R735.3[医药卫生—肿瘤]